Srikripa Devarakonda
Stock Analyst at Truist Securities
(3.15)
# 1,018
Out of 4,667 analysts
47
Total ratings
40.91%
Success rate
3.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,137 → $1,126 | $743.35 | +51.48% | 4 | Nov 1, 2024 | |
| KYMR Kymera Therapeutics | Reiterates: Buy | $54 → $53 | $44.05 | +20.32% | 3 | Nov 1, 2024 | |
| LLY Eli Lilly | Maintains: Buy | $1,000 → $1,033 | $739.27 | +39.73% | 3 | Oct 10, 2024 | |
| ABBV AbbVie | Maintains: Buy | $210 → $215 | $168.71 | +27.44% | 1 | Oct 10, 2024 | |
| BMEA Biomea Fusion | Upgrades: Buy | $54 | $6.28 | +759.87% | 1 | Sep 27, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Buy | $25 → $33 | $31.95 | +3.29% | 5 | Sep 19, 2024 | |
| INCY Incyte | Downgrades: Hold | $83 → $74 | $71.05 | +4.15% | 8 | Sep 18, 2024 | |
| PTGX Protagonist Therapeutics | Initiates: Buy | $60 | $40.65 | +47.60% | 1 | Sep 9, 2024 | |
| VSTM Verastem | Maintains: Buy | $18 → $15 | $3.79 | +295.78% | 7 | Aug 13, 2024 | |
| BIIB Biogen | Reiterates: Buy | $340 → $302 | $156.00 | +93.59% | 1 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $22.65 | +58.94% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 | $54.14 | +84.71% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $49.86 | +40.39% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $27.86 | -28.21% | 3 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $60 | $2.72 | +2,105.88% | 2 | Aug 11, 2023 |
Regeneron Pharmaceuticals
Nov 1, 2024
Maintains: Buy
Price Target: $1,137 → $1,126
Current: $743.35
Upside: +51.48%
Kymera Therapeutics
Nov 1, 2024
Reiterates: Buy
Price Target: $54 → $53
Current: $44.05
Upside: +20.32%
Eli Lilly
Oct 10, 2024
Maintains: Buy
Price Target: $1,000 → $1,033
Current: $739.27
Upside: +39.73%
AbbVie
Oct 10, 2024
Maintains: Buy
Price Target: $210 → $215
Current: $168.71
Upside: +27.44%
Biomea Fusion
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $6.28
Upside: +759.87%
Edgewise Therapeutics
Sep 19, 2024
Maintains: Buy
Price Target: $25 → $33
Current: $31.95
Upside: +3.29%
Incyte
Sep 18, 2024
Downgrades: Hold
Price Target: $83 → $74
Current: $71.05
Upside: +4.15%
Protagonist Therapeutics
Sep 9, 2024
Initiates: Buy
Price Target: $60
Current: $40.65
Upside: +47.60%
Verastem
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $3.79
Upside: +295.78%
Biogen
Aug 5, 2024
Reiterates: Buy
Price Target: $340 → $302
Current: $156.00
Upside: +93.59%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $22.65
Upside: +58.94%
Jun 18, 2024
Maintains: Buy
Price Target: $100
Current: $54.14
Upside: +84.71%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $49.86
Upside: +40.39%
Apr 3, 2024
Reiterates: Buy
Price Target: $20
Current: $27.86
Upside: -28.21%
Aug 11, 2023
Maintains: Buy
Price Target: $80 → $60
Current: $2.72
Upside: +2,105.88%